What question did this study set out to answer?

The review aims to explore the potential associations between cutaneous T-cell lymphoma and the use of biologic therapies for inflammatory skin diseases.

January 17, 2026International Journal of Dermatology and Venereology0 citationsOpen Access

Risk of Cutaneous T-Cell Lymphoma Linked to Biologic Therapy for Skin Diseases

Risk of Cutaneous T-Cell Lymphoma Associated with Biologic Therapy for Inflammatory Skin Diseases: A Comprehensive Review

View Full Paper

Authors

YBYue-Qi-Ji Bian ZLZhaorui Liu JLJie Liu

Discussion

Member takes

Overview

This review examines the link between biologic therapy and cutaneous T-cell lymphoma in skin disease management, highlighting significant implications.

Key Points

The review aims to explore the potential associations between cutaneous T-cell lymphoma and the use of biologic therapies for inflammatory skin diseases.
Comprehensive review of existing literature on CTCL and biologic therapies
Analysis of various biologic treatments including TNF-α, IL-4/IL-13, IL-17, and IL-12/IL-23 inhibitors
Comparison of immunological and molecular mechanisms involved in CTCL development
Identified a potential link between biologic therapies and an increased risk of CTCL development
Highlighted the need for further research to clarify the relationship and underlying mechanisms
Emphasized the importance of vigilant monitoring of patients receiving biologic therapies for skin diseases to detect any early signs of CTCL

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Bian et al. (2026) studied this question.

synapsesocial.com/papers/696b2696d2a12237a9349e51 https://doi.org/10.1097/jd9.0000000000000455

Ask AI

Helpful

Bookmark

View Full Paper

January 17, 2026International Journal of Dermatology and Venereology0 citationsOpen Access

Risk of Cutaneous T-Cell Lymphoma Linked to Biologic Therapy for Skin Diseases

Risk of Cutaneous T-Cell Lymphoma Associated with Biologic Therapy for Inflammatory Skin Diseases: A Comprehensive Review

View Full Paper

Authors

YBYue-Qi-Ji Bian ZLZhaorui Liu JLJie Liu

Discussion

Member takes

Overview

This review examines the link between biologic therapy and cutaneous T-cell lymphoma in skin disease management, highlighting significant implications.

Key Points

The review aims to explore the potential associations between cutaneous T-cell lymphoma and the use of biologic therapies for inflammatory skin diseases.
Comprehensive review of existing literature on CTCL and biologic therapies
Analysis of various biologic treatments including TNF-α, IL-4/IL-13, IL-17, and IL-12/IL-23 inhibitors
Comparison of immunological and molecular mechanisms involved in CTCL development
Identified a potential link between biologic therapies and an increased risk of CTCL development
Highlighted the need for further research to clarify the relationship and underlying mechanisms
Emphasized the importance of vigilant monitoring of patients receiving biologic therapies for skin diseases to detect any early signs of CTCL

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Bian et al. (2026) studied this question.

synapsesocial.com/papers/696b2696d2a12237a9349e51 https://doi.org/10.1097/jd9.0000000000000455

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Ask AI

Helpful

Bookmark

View Full Paper